

Contents

Evidence of potency and durability	2
• Study 006 – Longer time-to-treatment failure and durability of response with efavirenz + ZDV + 3TC: first analysis of full 1266 patient cohort from Study 006	3
• ACTG 364 – Comparison of the virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFV) with one or two new nucleoside analogs in nucleoside-experienced subjects: 48 week data	5
Evidence of efficacy in a range of combinations	6
• Study 043 – A Phase II, open-label, multicenter study to characterize the effectiveness and safety of efavirenz (EFV) in combination with stavudine (d4T) and lamivudine (3TC) in antiretroviral-naïve HIV-infected patients	7
• Study 044 – Efficacy of efavirenz (EFV) in combination with stavudine (d4T) and didanosine (ddI) in antiretroviral therapy-naïve HIV-infected patients	8
• Study 024 – A Phase II, open-label, multicenter study to characterize the effectiveness, safety, and pharmacokinetics of nelfinavir in combination with DMP 266 in antiretroviral therapy-naïve or nucleoside analogue-experienced HIV-infected patients	9
• Salvage therapy with abacavir (ABC) plus efavirenz (EFV) or nevirapine (NVP) in HIV-1 infected persons with CD4 cell count <100/mm ³ and prior protease inhibitor (PI) therapy	10
Evidence of efficacy in children	11
• ACTG 382 – Efavirenz in combination with nelfinavir and nucleoside reverse transcriptase inhibitors (NRTIs) is safe and virologically effective in HIV-infected children	12
Resistance	13
• Relative fitness of efavirenz (EFV, DMP 266)-resistant mutants of HIV-1	14
• Baseline prevalence of mutations linked to NNRTI resistance in patients enrolled in clinical studies of efavirenz	15
• Efavirenz response in NNRTI-experienced patients: results from the SUSTIVA™ Expanded Access program	16
Interactions and pharmacokinetics	17
• Population pharmacokinetics of efavirenz in Phase II studies and relationship with efficacy	18
• Pharmacokinetic interaction between efavirenz (EFV) and rifampin (RIF) in healthy volunteers	19
• Pharmacokinetics of efavirenz (EFV) and ritonavir (RIT) after multiple oral doses in healthy volunteers	20
• Lipid profiles and clinical lipodystrophy in Study 006 patients	21
• Maintenance of virologic control, changes in clinical lipodystrophy and metabolic parameters in persons switching from PI to efavirenz therapy	22
Viral sanctuaries	23
• Evaluation of lymph node viral burden in HIV-infected individuals receiving an efavirenz-based protease inhibitor-sparing HAART regimen	24
• High viral load in semen of human immunodeficiency virus type I-infected men at all stages of disease and its reduction by therapy with protease and non-nucleoside reverse transcriptase inhibitors	24
• Suppression of viral load in the female genital tract and cerebrospinal fluid (CSF) in patients on combination therapy including efavirenz	25